The
bleeding phenotype of
factor XI (FXI) deficiency is unpredictable.
Bleeding is usually mild and mostly occurs after injury. Although FXI deficiency renders antithrombotic protection, some patients might eventually develop
thrombosis or
atrial fibrillation, requiring
anticoagulant therapy. There is almost no evidence on the
bleeding risk in this scenario. Our retrospective study of 269 white FXI-deficient subjects (1995-2021) identified 15 cases requiring anticoagulation. They harbored 8 different F11 variants, mainly in heterozygosis (1 case was homozygote), and had mild to moderate deficiency (FXI:C: 20% to 70%). Two subjects (13.3%) had
bleeding history before anticoagulation.
Atrial fibrillation was the main indication (12/15; 80%). Fourteen patients started
therapy with
vitamin K antagonists (VKA), but 4 subjects were on direct oral
anticoagulants (DOACs) at the end of follow-up. Over >1000 months of anticoagulation, 2 mild
bleeding episodes in 2 patients (13.3%, 95% confidence interval: 3.7% to 37.9%) were recorded. No major/fatal events were reported. "Pre-post"
bleeding localization and severity did not change despite treatment. On VKA, drug dosing and management were also standard, unaltered by FXI deficiency. We provide the largest description of
anticoagulant use in FXI deficiency, and the first cases receiving DOACs. Although further studies are needed, our observations suggest that moderate FXI deficiency does not interfere with
anticoagulant management nor
bleeding risk.